Stifel lowers Crinetics stock price target to $58 from $60, keeps Buy rating

Crinetics (NASDAQ:CRNX) reported mixed Q2 2025 results, with revenue of $1 million surpassing expectations while EPS of -$1.23 missed consensus. Despite the earnings miss, Stifel maintained its Buy rating, albeit with a slight price target reduction to $58, citing the company's robust financial position, diversified pipeline, and ongoing progress towards the September 2025 PDUFA date for paltusotine in acromegaly. The firm highlights paltusotine's differentiated oral profile and the planned H2 2025 initiation of Phase 3 trials for atumelnant, underscoring Crinetics' strong commercialization prospects and continued pipeline advancement in rare endocrinology.

Analysis

Crinetics Pharmaceuticals (CRNX) presented mixed results for its second quarter of 2025, reporting a revenue beat of $1 million against a $750,110 forecast, but missing earnings expectations with an EPS of -$1.23 compared to the anticipated -$1.10. Despite the earnings shortfall, Stifel reiterated its Buy rating, adjusting its price target only slightly to $58.00 from $60.00. The analyst's confidence is anchored in the company's robust financial position, highlighted by a current ratio of 22.5 and a negligible debt-to-equity ratio of 0.04, which provides substantial capital as it nears commercialization. The core of the investment thesis remains its late-stage pipeline, led by paltusotine for acromegaly, which has a confirmed PDUFA date in September 2025. This drug's potential for significant market adoption is driven by its differentiated profile as an oral, once-daily treatment, a notable advantage over current injectable alternatives. The pipeline's depth is further underscored by plans to initiate Phase 3 trials for atumelnant in H2 2025 and the progression of earlier-stage assets, supporting Stifel's view of a diversified portfolio in the rare endocrinology space.

Key Decisions for Investors

• Investors should focus on the upcoming September 2025 PDUFA date for paltusotine as the most significant near-term catalyst, which could substantially de-risk the company's commercial outlook.
• The recent EPS miss should be weighed against the company's strong balance sheet, characterized by a 22.5 current ratio and minimal debt, which mitigates financing risk ahead of key product launches.
• Consider Stifel's maintained Buy rating and the pipeline's depth, including the initiation of Phase 3 trials for atumelnant, as key factors supporting a long-term positive thesis, despite the minor downward revision of the price target to $58.